(HRTX) Heron Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(HRTX) Heron Therapeutics, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Heron Therapeutics, Inc. BCG Matrix helps you see how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
No classic star
Heron Therapeutics, Inc. ends 2025 with no classic "star" because none of its products clearly combines dominant share and fast growth. The mix is still concentrated in a few specialty hospital brands, with APONVIE and ZYNRELEF the closest growth candidates, but not yet clear BCG leaders.
APONVIE 25 mg
APONVIE 25 mg is Heron Therapeutics, Inc.'s aprepitant injection for postoperative nausea and vomiting, launched in 2022. It sits in a growing perioperative market where PONV can affect up to 30% of surgical patients, so demand is real. Share is still being built, which makes APONVIE a potential Star, not a mature leader yet.
ZYNRELEF dual-acting analgesic
ZYNRELEF pairs bupivacaine with meloxicam in one fixed-dose, dual-acting shot, so it fits a Star in Heron Therapeutics, Inc. BCG matrix because it targets opioid-sparing postsurgical pain in a large, durable market. Adoption is still building across hospitals and ambulatory surgery centers, which keeps growth potential high.
Biochronomer platform
Biochronomer is Heron Therapeutics, Inc.’s controlled-release core platform, and it powers long-acting injectables designed to release medicine over days to weeks after one dose. It is a growth engine because it enables new products and life-cycle extensions, but it is not a separate, high-share revenue unit in Heron Therapeutics, Inc.’s reporting. In BCG Matrix terms, it fits best as a strategic enabler with upside, not a cash cow.
- Core tech, not standalone sales
- Supports days-to-weeks dosing
- Growth driver with low share
Perioperative hospital channel
Heron Therapeutics, Inc.'s perioperative hospital channel is the stronger Stars segment in its BCG mix: it targets nausea prevention and pain control, and it benefits from the shift to outpatient surgery plus opioid-sparing care. U.S. ambulatory surgery accounts for more than 60% of surgeries, so demand can scale faster than the legacy oncology antiemetic base.
- Outpatient care supports faster channel growth.
- Pain and nausea fit opioid-reduction trends.
- Perioperative demand beats legacy oncology growth.
- Channel can drive better margin mix.
Heron’s 2025/2026 Growth Bets: APONVIE and ZYNRELEF Lead the Way
Heron Therapeutics, Inc. has no true Stars in 2025/2026, but APONVIE and ZYNRELEF are the closest growth bets. APONVIE targets a PONV market that affects up to 30% of surgical patients, while ZYNRELEF rides opioid-sparing pain care in a U.S. outpatient surgery base that handles over 60% of procedures.
| Asset | Star fit | Key fact |
|---|---|---|
| APONVIE | Potential | Launched 2022; PONV up to 30% |
| ZYNRELEF | Potential | Opioid-sparing pain; outpatient >60% |
What is included in the product
Detailed Word Document
Heron Therapeutics’ BCG Matrix maps its product portfolio into Stars, Cash Cows, Question Marks, and Dogs for strategy.
Editable Excel File
BCG Matrix for Heron Therapeutics as a pain point reliever, with a clean, C-level-ready view of each business unit.
Reference Sources
Provides a credible source trail for Heron Therapeutics, Inc., making key assumptions easier to verify, defend, and update for better decisions.
Cash Cows
CINVANTI 130 mg
CINVANTI 130 mg is Heron Therapeutics, Inc.'s most established commercial brand and the clearest recurring cash generator in its portfolio. As an IV aprepitant used to prevent chemotherapy-induced nausea and vomiting, it anchors steady hospital and oncology demand, while Heron also reports ZYNRELEF as a newer growth driver.
NK1 antiemetic franchise
Heron Therapeutics, Inc.'s NK1 antiemetic franchise, led by aprepitant products, holds an entrenched spot in supportive oncology care because antiemetic prophylaxis is used with each chemotherapy cycle. That makes demand repeatable and less volatile than new perioperative launches. It is a mature cash cow, but I can’t verify 2025/2026 revenue or share data from live filings here.
2017 FDA approval
CINVANTI has been on the market since its 2017 FDA approval, so it is Heron Therapeutics, Inc.'s most mature branded asset. That older age usually means lower launch spending and steadier cash flow than newer products. In BCG terms, this maturity fits a Cash Cow profile because the brand can keep generating revenue without heavy growth investment.
Hospital formulary base
CINVANTI is already embedded in hospital and infusion-center formularies, so the value now comes from repeat ordering, not heavy launch spend. That makes the hospital base a Cash Cow: access stays sticky, buying is recurring, and cash flow is more predictable than in a push-growth phase. For Heron Therapeutics, Inc., the key is defending formulary slots and refill volume.
- Formulary access drives repeat use
- Lower spend, steadier orders
- Cash flow becomes more predictable
Oncology supportive care revenue
Heron's oncology antiemetic sales are its most durable revenue stream because hospitals and clinics reorder supportive care products again and again. Unlike pipeline assets, these medicines are used in routine treatment cycles, so the segment fits the "cash cow" label in a BCG Matrix.
Repeat use supports stable demand.
Lower risk than pipeline-driven bets.
Best fit for cash generation.
CINVANTI: Heron’s recurring cash generator
CINVANTI, approved in 2017, is Heron Therapeutics, Inc.'s clearest Cash Cow because antiemetic use repeats with each chemotherapy cycle, supporting steady hospital reorder volume. Its value is not fast growth; it is durable, formulary-locked cash flow with lower launch spend. ZYNRELEF is newer, so the mature oncology antiemetic base still does the heavy cash work.
| Cash Cow asset | Key fact | BCG role |
|---|---|---|
| CINVANTI | FDA approved 2017 | Recurring cash generator |
Preview Before You Purchase
Heron Therapeutics, Inc. Reference Sources
This preview shows the exact Heron Therapeutics, Inc. BCG Matrix document you’ll receive after purchase. No demo pages or placeholder content—just the same fully formatted file. Once purchased, it’s ready for immediate use in strategy, analysis, or presentation.
Dogs
SUSTOL 10 mg
SUSTOL 10 mg is Heron Therapeutics, Inc.'s extended-release granisetron injection, approved in 2016 for chemotherapy-induced nausea and vomiting. By end-2025, it looks like the weakest commercial brand in the portfolio, with little visible growth versus the newer pain and antiemetic products. In BCG terms, it fits a "Dog": low share, low momentum, and limited strategic upside.
5-HT3 crowded market
Granisetron sits in a crowded 5-HT3 antiemetic class with many low-cost rivals, so Heron Therapeutics, Inc. has limited room to lift share. Older 5-HT3 drugs face pressure from familiar options like ondansetron and palonosetron, which keeps pricing power weak. In BCG terms, this is a Dog: low growth, weak differentiation, and modest return potential.
Legacy A.P. Pharma asset
SUSTOL is a legacy A.P. Pharma asset, not Heron Therapeutics, Inc.'s main growth engine anymore. In Heron Therapeutics, Inc.'s BCG view, slow-moving legacy products with limited demand and low strategic fit belong in "Dogs." That makes SUSTOL a weak-momentum asset, better for harvest or run-off than fresh investment.
Low adoption profile
SUSTOL has not turned into a must-have drug, so Heron Therapeutics still fits a Dog on low adoption and weak growth. Hospital and oncology buyers have had cheaper, entrenched substitutes for years, and that keeps switch rates low. In BCG terms, a small share in a slow market is classic Dog behavior.
- Low share, low growth
- Substitutes limit uptake
- No dominant market position
Minimal strategic pull
SUSTOL has minimal strategic pull in Heron Therapeutics, Inc.'s portfolio because the Company has centered growth on CINVANTI, APONVIE, and ZYNRELEF. SUSTOL looks more like a maintenance asset than a capital sink, since companies rarely pour money into products with weak upside.
That makes it a cash trap, not a growth driver, especially when R&D and sales spend must support higher-return brands. In FY2025, Heron’s strategy still pointed to the newer, larger-opportunity products, with SUSTOL outside the main expansion story.
- SUSTOL is not the main growth focus.
- CINVANTI, APONVIE, ZYNRELEF lead strategy.
- Low upside limits capital allocation.
- More likely cash drain than catalyst.
SUSTOL: Heron’s Clear Dog and Harvest Asset
SUSTOL is Heron Therapeutics, Inc.'s clearest Dog: a legacy antiemetic in a crowded 5-HT3 class, with no separate FY2025 sales disclosed and little visible growth. Heron Therapeutics, Inc. now focuses capital on CINVANTI, APONVIE, and ZYNRELEF, so SUSTOL looks more like a harvest asset than a growth driver.
| Item | FY2025 data | BCG |
|---|---|---|
| SUSTOL | No separate sales disclosed | Dog |
Question Marks
APONVIE 2022 launch
APONVIE, launched in 2022, is still early in its commercial life and sits in Heron Therapeutics, Inc.'s Question Mark bucket. It targets postoperative nausea and vomiting, a perioperative need that affects about 30% to 40% of all surgical patients and up to 80% of high-risk patients. To move toward Star status, APONVIE needs faster share gains, stronger hospital adoption, and better repeat use.
ZYNRELEF 2021 launch
ZYNRELEF, launched in 2021, is Heron Therapeutics, Inc.’s newer non-opioid post-surgical pain product, and it fits the question mark box because demand can still expand fast, but share remains limited. Heron said ZYNRELEF generated $26.6 million in 2024 net product sales, up from $20.8 million in 2023, showing early traction but not scale yet. The pain-control market is large, so wider hospital and surgeon adoption could drive strong growth, but it still needs broader use.
HTX-034 Phase Ib/II
HTX-034 is Heron Therapeutics, Inc.'s next-generation postoperative pain candidate and fits the BCG Question Mark bucket because it is still in Phase Ib/II. That stage means the asset is early and not yet de-risked, so the upside is high if efficacy and safety hold, but the failure risk is also high. For Heron Therapeutics, Inc., HTX-034’s value will depend on moving from Phase 1/2 data to later-stage proof, where clinical and commercial odds improve.
Postoperative pain market
The non-opioid postsurgical pain market is growing as hospitals and ambulatory surgery centers shift toward opioid-sparing care; U.S. ambulatory surgery alone handles more than 50 million procedures a year. Heron Therapeutics, Inc. has a real opening with ZYNRELEF, but in a BCG Matrix this still looks like a Question Mark because share is not yet dominant.
That means the upside is tied to faster adoption, better payer access, and stronger surgeon pull-through.
New label expansion
Heron Therapeutics, Inc. still needs new labels to broaden use beyond current surgeries and care settings; that makes these assets question marks in the BCG Matrix. If adoption is fast, each new indication can lift share quickly, but the upside is still unproven until surgeons and hospitals switch in volume.
- Growth needs more procedures and sites
- Adoption can drive share gains fast
- Until uptake proves out, stay cautious
Heron’s Question Marks Could Turn into Growth Winners
Heron Therapeutics, Inc.’s Question Marks are APONVIE, ZYNRELEF, and HTX-034: each has growth potential, but share is still early or unproven. ZYNRELEF posted $26.6 million in 2024 net product sales, up from $20.8 million in 2023, while APONVIE and HTX-034 still need broader uptake and later-stage proof. If hospital adoption and payer access improve, these assets can gain share fast.
| Asset | 2024 data | BCG view |
|---|---|---|
| ZYNRELEF | $26.6M sales | Question Mark |
| APONVIE | Early launch | Question Mark |
| HTX-034 | Phase Ib/II | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.